Eribulin Approval in Advanced Liposarcoma – Successful Drug or a Weaker Methodology?

Sameer Rastogi; Vineet Gupta

doi:10.4103/0971-5851.203492

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(01): 2-3
DOI: 10.4103/0971-5851.203492

Editorial Commentary

Eribulin Approval in Advanced Liposarcoma – Successful Drug or a Weaker Methodology?

Autoren

Sameer Rastogi

Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi
Vineet Gupta

Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi

Abstract

als PDF herunterladen

PDF (283 kb)

Referenzen

References
1 Schoffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. Lancet 2016;387:1629-37.
2 Young RJ, Woll PJ. Eribulin in soft-tissue sarcoma. Lancet 2016;387:1594-6.
3 Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine- reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-94.
4 Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: Importance, indications, and interpretation. Lancet 2005;365:176-86.
5 Maggioni AP, Darne B, Atar D, Abadie E, Pitt B, Zannad F; 5th Cardiovascular Clinical Trialists Workshop. FDA and CPMP rulings on subgroup analyses. Cardiology 2007;107:97-102.
6 Saad ED, Buyse M. Statistical controversies in clinical research: End points other than overall survival are vital for regulatory approval of anticancer agents. Ann Oncol 2016;27:373-8.
7 Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, et al. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: Evaluation of progression-free survival, duration of disease control, and time to failure of strategy- An Aide et Recherche en Cancerologie Digestive Group Study. J Clin Oncol 2011;29:4199-204.
8 Morita S, Sakamaki K, Yin G. Detecting overall survival benefit derived from survival postprogression rather than progression-free survival. J Natl Cancer Inst 2015;107. pii:Djv133.